摘要
目的分析阿仑膦酸钠治疗糖尿病合并骨质疏松的临床效果。方法该院2017年9月-2018年9月接收糖尿病合并骨质疏松患者80例。根据双盲分组方法将患者分为两组,对照组与观察组均40例。对照组患者使用临床常规药物治疗,观察组患者采用阿仑膦酸钠治疗。对照两组患者临床效率。结果统计两组患者临床治疗效率,对照组为75.0%,观察组为95.0%,差异有统计学意义(P<0.05);两组患者治疗后的糖尿病相关指标均改善,相对比观察组患者改善效果要优于对照组,检验数据,差异有统计学意义(P<0.05);治疗前两组患者的各项骨密度指标无区别,治疗后骨密度指标明显改善,且对比治疗后观察组与对照组差异有统计学意义(P<0.05)。结论相对比临床常规使用的药物,糖尿病合并骨质疏松患者应用阿仑膦酸钠治疗效果显著,可改善患者各项指标,应用价值较高。
Objective To analyze the clinical effect of alendronate on diabetes and osteoporosis. Methods From September2017 to September 2018, our hospital received 80 patients with diabetes and osteoporosis. Patients were divided into two groups according to the double-blind grouping method, and 40 patients in both the control group and the observation group.Patients in the control group were treated with conventional clinical drugs, and patients in the observation group were treated with alendronate. The clinical efficiency of the two groups of patients was compared. Results The clinical treatment efficiency of the two groups was 75.0% in the control group and 95.0% in the observation group, which was statistically significant(P<0.05). The diabetes-related indexes of the two groups were improved after treatment, and the improvement effect of the observation group was compared. To be better than the control group, the test data was, which was statistically significant(P<0.05). There was no difference in the bone mineral density indexes between the two groups before treatment. The bone mineral density index was significantly improved after treatment, and the difference between the observation group and the control group after the treatment was compared, the difference was statistically significant(P<0.05). Conclusion Compared with the drugs used routinely in clinical practice, the treatment of patients with diabetes and osteoporosis with alendronate has a significant effect, which can improve the indicators of patients and have higher application value.
作者
张小青
ZHANG Xiao-qing(Department of Endocrinology,Jining First People's Hospital,Jining,Shandong Province,272011 China)
出处
《糖尿病新世界》
2019年第21期1-2,共2页
Diabetes New World Magazine